Table 2.
Iron parameters and blood Hb concentration at baseline and at week 17 in DIALOGUE 1
| Parameter | Molidustat |
Placebo |
||||||
|---|---|---|---|---|---|---|---|---|
| overall |
non-iron users |
overall |
non-iron users |
|||||
| baseline | week 17 | baseline | week 17 | baseline | week 17 | baseline | week 17 | |
| Hb, g/dL | 9.5±0.7 (101) | 11.0±1.2 (43) | 9.4±0.8 (53) | 10.8±1.3 (22) | 9.5±0.6 (20) | 9.8±14.1 (18) | 9.4±0.7 (8) | 10.05±1.0 (6) |
| Hepcidin, ng/mL | 36.0±29.9 (101) | 18.5±19.8 (40) | 40.3±35.4 (53) | 11.5±10.9 (22) | 38.0±30.8 (20) | 41.0±33.7 (18) | 35.0±15.3 (8) | 31.8±27.8 (6) |
| Ferritin, µg/L | 201.4±149.6 (101) | 98.3±89.5 (40) | 220.8±176.3 (53) | 71.7±69.4 (22) | 221.0±163.9 (20) | 215.9±149.1 (18) | 269.1±173.8 (8) | 241.2±196.0 (6) |
| Iron, µg/dL | 81.3±34.2 (101) | 67.6±29.3 (40) | 86.5±39.8 (53) | 63.5±26.6 (22) | 82.5±21.8 (20) | 68.3±28.7 (18) | 87.0±28.9 (8) | 51.6±10.0 (6) |
| TSAT, % | 34.2±13.3 (100) | 27.9±12.5 (40) | 36.3±13.6 (53) | 26.2±12.4 (22) | 35.2±9.5 (18) | 29.6±11.2 (18) | 35.1±9.8 (7) | 23.0±6.8 (6) |
| TIBC, pmol/L | 43.4±9.6 (100) | 45.6±10.3 (40) | 43.1±9.8 (53) | 46.6±10.7 (22) | 41.5±6.9 (18) | 41.3±7.0 (18) | 41.1±8.5 (7) | 41.5±6.5 (6) |
Data are mean ± SD (n).
Hb, hemoglobin; DIALOGUE, DaIly orAL treatment increasing endOGenoUs Erythropoietin; TSAT, transferrin saturation; TIBC, total iron binding capacity.